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Abstract
Biliary dyspepsia presents as biliary colic in the absence of explanatory structural abnormalities. Causes include gallbladder
dyskinesia, sphincter of Oddi dysfunction, biliary tract sensitivity, microscopic sludges, and duodenal hypersensitivity. However, no
consensus treatment guideline exists for biliary dyspepsia. We investigated the effects of medical treatments on biliary dyspepsia.
We retrospectively reviewed the electronic medical records of 414 patients who had biliary pain and underwent cholescintigraphy
from 2008 to 2018. We enrolled patients who received litholytic agents and underwent follow-up scans after medical treatment. We
divided the patients into the GD group (biliary dyspepsia with reduced gallbladder ejection fraction [GBEF]) and the NGD group (biliary
dyspepsia with normal GBEF). We compared pre- and post-treatment GBEF and symptoms.
Among 57 patients enrolled, 40 (70.2%) patients had significant GBEF improvement post-treatment, ranging from 34.4±22.6% to
53.8±26.8% (P< .001). In GD group (n=35), 28 patients had GBEF improvement after medical treatment, and value of GBEF
significantly improved from 19.5±11.0 to 47.9±27.3% (P< .001). In NGD group (n=22), 12 patients had GBEF improvement after
medical treatment, but value of GBEF did not have significant change. Most patients (97.1% in GD group and 81.8% in NGD group)
had improved symptoms after medical treatment. No severe complication was reported during treatment period.
Litholytic agents improved biliary colic in patients with biliary dyspepsia. Therefore, these agents present an alternative treatment
modality for biliary dyspepsia with or without gallbladder dyskinesia. Notably, biliary colic in patients with gallbladder dyskinesia
resolved after normalization of the GBEF. Further prospective and large-scale mechanistic studies are warranted.
Abbreviations: CNU = combination of chenodeoxycholic acid and ursodeoxycholic acid, DISIDA = technetium-99m diisopropyl
iminodiacetic acid cholescintigraphy, GB = gallbladder, GBEF = gallbladder ejection fraction, GD = gallbladder dyskinesia, NGD =
non-gallbladder dyskinesia, UDCA = ursodeoxycholic acid.
Keywords: biliary dyspepsia, gallbladder dyskinesia, litholytic agent1. Introduction
Biliary dyspepsia is defined as the presence of biliary pain with no
organic, systemic, or metabolic cause.[1] The causes of biliary
dyspepsia include gallbladder dyskinesia (GD), sphincter of Oddi
dysfunction, biliary tract sensitivity, microscopic sludges,
duodenal hypersensitivity, and parasitic infestation.[2] Among
these causes, GD, also referred to as functional gallbladder (GB)
disorder or GB dysfunction, is a rare functional disorder definedEditor: Raffaele Pezzilli.
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as biliary pain in the absence of gallstone or other structural
pathology. The Rome IV criteria describe in detail the diagnostic
criteria for biliary pain in the epigastrium and/or right upper
quadrant.[3] The diagnosis of biliary pain due to GD is supported
by a low gallbladder ejection fraction (GBEF) on GB scintigraphy
and normal laboratory test results.[3,4] The prevalence of GD has
increased due to the introduction of diagnostic modalities such as
GB scintigraphy.[5] Several studies have examined the prevalenceCT of Korea (NRF-2018R1C1B5045210) and a faculty research grant from the
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biliary pain without gallstone in Italy; 2.0% of the enrolled
patients had biliary dyspepsia,[6] and the prevalence of GD
differed according to sex. Other large-population studies
showed that GD was more common in females (20.7%) than
in males (7.6%).[7,8]
Medical and surgical therapies can be used to treat biliary
dyspepsia according to its cause, but no consensus treatment
guideline has been established. A previous study of the efficacy of
cholecystectomy for biliary dyskinesia showed that patients who
received cholecystectomy exhibited significant symptom im-
provement compared with nonsurgical patients.[9]
However, surgery as the primary treatment method for GD is
burdensome for elderly patients and those with comorbidities. In
such patients, medical treatment for GD is preferred. However,
data on the effect of medical treatment on GD are scarce.
We investigated the effects of medical treatments on biliary
dyspepsia, with a focus on 2 litholytic agents. The primary
outcomes were increased GBEF and symptom improvement after
medical treatment.2. Materials and methods
2.1. Patients
In this retrospective study, we reviewed the electronic medical
records of 414 patients who presented with biliary pain and
underwent technetium-99m diisopropyl iminodiacetic acid
(DISIDA) cholescintigraphy between July 2008 and August
2018, in 6 tertiary hospitals. All reviewed patients were≥18 years
and of Korean. Exclusion criteria were patients with no post-
treatment DISIDA scan; an organic lesion causing biliary pain; no
medical treatment; abnormal laboratory test results (serum levels
of aspartate transaminase/alanine transaminase, bilirubin, gam-
ma-glutamyl transferase, amylase, or lipase); acute or episodic
symptoms; and history of incomplete electronic medical records.
In addition, patients who had impaired mobility, renal
insufficiency, electrolyte imbalance, and history of abdominal
surgery were also excluded.
The study protocol conformed to the ethical guidelines of the
World Medical Association Declaration of Helsinki and was
approved by the Institutional Review Board of Gangnam
Severance Hospital (IRB No: 3-2019-0244). Informed consent
was not required because this study was a retrospective analysis
of existing administrative and clinical data.2.2. Data collection
Data were retrospectively extracted from the electronic medical
records of 6 tertiary hospitals. The data included demographic,
clinical, laboratory, and imaging parameters, and the findings of
upper gastrointestinal endoscopies performed at the time of
treatment initiation.
Demographic data included age, sex, body mass index (BMI),
and personal and medical histories. Imaging and GBEF data were
collected from initial and follow-up DISIDA scans. Imaging
parameters included abdominal ultrasonography, abdominal
computed tomography, magnetic resonance imaging, and
endoscopic ultrasonography. Regarding litholytic agents, we
collected data on the type, duration, and side effects of
medication. We analyzed data from patients who received
2 litholytic agents: Ursa (ursodeoxycholic acid [UDCA];2
Daewoong Pharm. Co. Ltd., Seoul, South Korea) and CNU
(magnesium trihydrate salt of chenodeoxycholic acid and
ursodeoxycholic acid [CNU]; Myungmoon Pharm. Co., Seoul,
South Korea).2.3. DISIDA scanning
All enrolled patients underwent pre- and post-treatment DISIDA
scans, during which GBEF values were measured and recorded.
The method used for DISIDA scanning is described in detail
below.[10]
The DISIDA scan was performed after the patient had fasted
overnight. Each subject was given 8 mCi DISIDA intravenously
under a large-field-of-view gamma camera. Serial hepatobiliary
analogue images were obtained at 5, 10, 20, 30, 45, and 60
minutes after the injection or until the GB was adequately filled.
Immediately after completion of the filling phase, the patients
drank 200 mL milk containing about 13 g fat (130 kcal).
Analogue images were recorded 30 minutes after ingestion of the
milk. The GBEF was derived by calculating the counts in the GB
before and 30 minutes after ingestion of the milk. Background
regions over the liver were also generated and subtracted from the
GB counts to derive the net GB count.2.4. Definitions
Biliary dyspepsia defined as biliary colic without any organic,
systemic, or metabolic origin. Biliary colic was steady pain in the
right upper quadrant and/or epigastric area, lasting for at least 30
minutes according to Rome IV criteria.[4] To exclude patients,
who have organic, systemic, and metabolic origin, we reviewed
the result of laboratory and imaging parameters, and the findings
of upper gastrointestinal endoscopies. These enrolled patients,
who had biliary dyspepsia, were divided into 2 groups according
to the results of the initial DISIDA scans. Patients who had
reduced initial GBEFs (< 38%) were allocated to the GD group.
Patients who had normal initial GBEFs (≥ 38%)were allocated to
the non-gallbladder dyskinesia (NGD) group.
After medical treatment, we evaluated the GBEFs and
symptoms of the patients. The GBEF was evaluated by follow-
up DISIDA scan and classified as showing improvement, no
change, or deterioration. The improvement of symptoms after
treatment was also evaluated.2.5. Statistical analysis
Continuous variables are reported as means± standard devia-
tions. We used Student t test or the Wilcoxon rank-sum test to
compare continuous variables between the groups. Categorical
variables are reported as numbers and percentages and were
compared by Chi-squared test or Fisher exact test. Statistical
analysis was performed using the SPSS version 23.0 (IBM Corp.,
Armonk, NY). Two-tailed P values< .05 were considered to
indicate statistical significance.3. Results
3.1. Patients
In total, 414 patients underwent DISIDA scans for biliary pain
between July 2008, and August 2018. Among these patients, 6
were excluded because their biliary pain was determined to be of
Figure 1. Study flow chart. We enrolled in this retrospective study 57 patients with biliary pain who underwent cholescintigraphy. DISIDA, technetium-99m
diisopropyl iminodiacetic acid cholescintigraphy; GB, gallbladder; GBEF, gallbladder ejection fraction; NGD, biliary pain with normal gallbladder ejection fraction;
GD, biliary pain with reduced gallbladder ejection fraction.
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diabelack of post-treatment DISIDA scan (n=313)
(2) receipt of surgical treatment for biliary pain (n=20)
(3) incompleteness of electronic medical records (n=16)
(4) receipt of no treatment (n=2). As a result, 57 patients were
enrolled in this study (Fig. 1)
3.2. Baseline characteristics
The mean age of the participants was 46.4±15.9 years, and
females were predominant (71.9%). The average BMI was 23.3±
5.0 kg/m2, and 10 (17.5%) patients were obese according to the
Asia-Pacific criteria. Three patients were current smokers, and 9
patients had histories of alcohol consumption. Two and 8 patients
had diabetes mellitus and hypertension, respectively (Table 1).ble 1
eline characteristics of the study population.
ables All patients (N=57)
(yr, mean±SD) 46.4±15.9
(n, %) 16 (28.1)
(kg/m2, mean±SD) 23.3±5.0
ent smoker (n, %) 3 (5.3)
hol history (n, %) 9 (15.8)
(n, %) 2 (3.5)
rtension (n, %) 8 (14.0)
l DISIDA scan
retreatment GBEF (%, mean±SD) 34.4±22.6
D diagnoses based on pretreatment GBEF (n, %) 35 (61.4)
body mass index, DISIDA= technetium-99m diisopropyl iminodiacetic acid cholescintigraphy, DM=
tes mellitus, GB=gallbladder, GBEF=gallbladder ejection fraction, GD=gallbladder dyskinesia.
3
Table 2 shows the litholytic agents prescribed for biliary
dyspepsia. Among the patients, 19 (33.3%) received CNU and
38 (66.7%) received UDCA. The mean treatment duration was
15.6±20.1 months.3.3. Result of DISIDA scan
On initial DISIDA scans, the mean pre-treatment GBEF was 34.4
±22.6%, and 35 (61.4%) patients had GBEFs<38% (Table 1).
Therefore, 35 patients were diagnosed with GD, and the
remaining 22 patients were allocated to the NGD group. Mean
time interval between initial and follow-up DISIDA scan was 8.6
±6.8 months.
The quantitative changes in the GBEF are shown in Table 3.
For all patients, the initial mean GBEF (34.4±22.6%) was
significantly lower than that after medical treatment (53.8±
26.8%; P< .001). In addition, UDCA significantly increased the
GBEF from 29.4±18.8% to 51.2±26.4% (P< .001) for allTable 2
Litholytic agents prescribed to the study population.
Variables All patients (N=57)
Litholytic agents (n, %)
CNU 19 (33.3)
UDCA 38 (66.7)
Duration of medication (months, mean±SD) 15.6±20.1
Improved biliary pain (n, %) 52 (91.2)
GD group 34/35 (97.1)




CNU= combination of chenodeoxycholic acid and ursodeoxycholic acid, GD=gallbladder dyskinesia,
NGD=non-gallbladder dyskinesia, UDCA=ursodeoxycholic acid.
Figure 2. Pre- and post-treatment gallbladder ejection fractions. (A) Dot plot and (B
(D). Dot plots for the patients in the GD group who received CNU (E) and UDCA (
gallbladder ejection fraction; GD, biliary pain with reduced gallbladder ejection fra
Table 3
Comparison of pre- and post-treatment GBEFs.
Pretreatment Post-treatment P-value
All patients (n=57) 34.4±22.6 53.8±26.8 <.001
CNU (n=19) 44.5±26.4 58.9±27.5 .107
UDCA (n=38) 29.4±18.8 51.2±26.4 <.001
GD group (n=35) 19.5±11.0 47.9±27.3 <.001
CNU (n=9) 21.4±11.8 46.4±30.5 .035
UDCA (n=26) 18.9±10.8 48.4±26.8 <.001
NGD group (n=22) 58.1±14.4 63.1±23.6 .401
CNU (n=10) 65.3±15.9 70.2±19.7 .548
UDCA (n=12) 52.1±10.2 57.2±25.7 .533
CNU=combination of chenodeoxycholic acid and ursodeoxycholic acid, GB=gallbladder, GBEF=
gallbladder ejection fraction, GD=gallbladder dyskinesia, NGD=non-gallbladder dyskinesia, UDCA=
ursodeoxycholic acid.
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patients. Patients receiving CNU treatment also showed a
significant difference in the GBEF (P= .107). Figure 2 (A) and
(B) are pre- and post-treatment GBEF dot plots for all patients.
In the GD group, the mean pre-treatment GBEF (19.5%±
11.0%) was significantly lower than that after medical treatment
(47.9±27.3%, P< .001; Table 3). In patients with GD, CNU and
UDCA significantly increased the GBEF (Fig. 2D). CNU
treatment increased the GBEF from 21.4±11.8% to 46.4±
30.5% (P= .035; Fig. 2E), and UDCA treatment increased the
GBEF from 18.9±10.8% to 48.4±26.8% (P< .001; Fig. 2F).
The GBEF did not change significantly in the NGD group
(P= .401; Table 3, Fig. 2C).
Figure 3 shows representative DISIDA scans of a treatment-
responsive patient with GD (A) before and (B) after CNU
treatment. This patient’s GBEF was 20.1% before treatment and
85.0% after treatment.) paired dot plot for all patients. Dot plots for the NGD group (C) and GD group
F).
∗
P< .05. GBEF, gallbladder ejection fraction; NGD, biliary pain with normal
ction.
Figure 3. Representative DISIDA scans of a patient with GDwith improved GBEF. DISIDA scans (A) before medical treatment (GBEF=20.1%) and (B) after medical
treatment (GBEF=85.0%). DISIDA, technetium-99m diisopropyl iminodiacetic acid cholescintigraphy; GB, gallbladder; GD, gallbladder dyskinesia; GBEF,
gallbladder ejection fraction.
Kim et al. Medicine (2020) 99:34 www.md-journal.com3.4. Symptom improvement after medical treatment
Biliary pain symptoms improved in 52 (91.2%) patients (97.1%
in the GD group, 81.8% in the NGD group). The rate of
symptom improvement was significantly greater in the GD group
than in the NGD group (P< .001).
Among the 35 patients with GD, all 22 patients with
normalized GBEFs after medical treatment experienced improve-
ment of their biliary pain. Of the 13 patients who had persistent
GD (as indicated by their GBEFs) despite medical treatment, 12
patients had improved symptoms and 1 patient had persistent
symptoms (Fig. 1).
Two patients had side effects while using UDCA (diarrhea and
constipation, respectively). However, these side effects were not
serious enough to warrant discontinuation of the treatment.5
4. Discussion
We determined that litholytic agents improved symptoms of
biliary dyspepsia. In addition, patients with GD experienced
significant improvement in symptoms and the GBEF after
medical treatment. Although the mechanism of GD is unclear,
researchers have made plausible suggestions. First, a narrowed
cystic duct can induce incomplete GB emptying, eventually
causing chronic cholecystitis and biliary pain.[11] Another group
reported an association between the cystic duct, rather than the
common bile duct or sphincter of Oddi, and GB dysfunction.[12]
Second, microlithiasis is associated with GD. One previous study
compared GB emptying among 3 groups (healthy controls,
patients with gallstones, and patients with microlithiasis).[13] The
GBEF was significantly lower in patients with microlithiasis than
Kim et al. Medicine (2020) 99:34 Medicinein control patients. Beyond these potential mechanisms, several
factors, such as prostaglandin E2, are also associated with the
pathogenesis of GD.[4,14,15]
Among these factors,wehypothesized thatUDCAmighthavean
effect on dissolution of microlithiasis, thereby, improved GD.
However, furtheranalysis ofbile fromthesepatients iswarranted to
evaluate the effect of medical treatment with UDCA on micro-
lithiasis, and UDCA was shown to correct this bile abnormality.
We used a GBEF cutoff value for GD of 38%. No cut-off value
for GD has been established, although values of 35% to 50%
have been set in previous studies.[16,17] Further research to
establish uniform cutoff value for GD should be performed.
However, our study will be meaningful to compare incidence of
GD and result of our study with other studies, which use cutoff
value as 38%.
In patients with GD in this study, the proportion of symptom
improvement (97.1%) was not consistent with that of GBEF
normalization (80.0%). Whether this effect was due to medical
treatment is not certain, because no GBEF cut-off value has been
evaluated formally or established.[4] Patients with GD may
respond to medical treatments, such as UDCA, but the sample for
this study was too small for such an evaluation. Patients who had
biliary pain and normal GBEFs experienced significant improve-
ment in pain symptoms. Interestingly, the GBEF was not
significantly changed after treatment. The mechanism of
symptom improvement was not clear because of the heterogene-
ity of theNGD group. The causes of biliary dyspepsia in theNGD
group could include sphincter of Oddi dysfunction, biliary tract
sensitivity, and microscopic gallstones or sludges.[18,19]
Our study has several strengths over previous studies. First,
biliary pain and GBEF values were required to diagnose GD.
Most previous studies that aimed to evaluate treatment effects
focused solely on symptom improvement. Symptoms can be
subjective, even when evaluated using a pain scale. We evaluated
the effects of medication on not only symptoms but also the
GBEF, a more objective and reliable measure. Second, our study
enrolled patients with GD and NGD. Many patients visit
outpatient clinics because of biliary pain located in the
epigastrium and/or right upper quadrant. Physicians perform
various tests, including laboratory and imaging tests, as part of
their initial evaluation.When the results of these tests are normal,
many clinicians suspect functional gastrointestinal disorder or
irritable bowel syndrome. A previous study showed that the
evaluation of GB function is necessary to exclude GD in patients
who present with biliary pain.[20] Our study confirms this finding
in a larger number of patients.
This study has several limitations. First, this study was
retrospective and sample size was too small. When patients have
biliary colic, DISIDA scan is not a routine test in our clinic.
Moreover, patients tend to not be performed follow-up DISIDA
scan when they recover from symptoms. Because of this small
sample size, it is hard to analyze control group. Only 2 patients
did not receive any treatment. Prospective and large-scale study is
warranted. Second, we evaluated symptoms by retrospectively
reviewing patients’ electronic medical records. Further investiga-
tion of symptoms using a method such as a visual analogue scale
is needed because the pain evaluation was subjective. Third, we
evaluated the effects of litholytic agents, but did not determine
whether medical treatment is superior to surgical treatment.
Further study of medical and surgical treatments is thus
warranted. Fourth, according to the Rome IV criteria, GD is
not the only condition that induces biliary pain; other conditions6
(e.g., sphincter of Oddi dysfunction and duodenal hypersensitiv-
ity) can also induce biliary pain.[21] Because we reviewed medical
records that included DISIDA scans, we were unable to diagnose
these other conditions. For example, manometry for the
diagnosis of sphincter of Oddi dysfunction is not a routine test.
Therefore, the NGD group was heterogeneous in terms of the
causes of biliary dyspepsia.
In conclusion, the litholytic agents UDCA andCNUmodulated
the GBEF and induced symptom improvement in patients with
biliary dyspepsia. In addition, the complication rate of medical
treatment was low. Therefore, treatment with litholytic agents
may be an alternative to surgical treatment for biliary dyspepsia,
especially in patients for whom surgery is contraindicated.
Notably, biliary pain resolved after normalization of the GBEF in
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